- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.09. | Barinthus Bio joins forces with metabolic disease biotech in reverse merger | ||
| 30.09. | AnaptysBio plans to split biotech and Jemperli royalties into separate businesses | ||
| 30.09. | Opus sets sights on FDA talks after posting pediatric gene therapy data | ||
| 30.09. | Pfizer's new prize Metsera touts 14% weight loss, 'class-leading tolerability' for lead GLP-1 drug | ||
| 30.09. | Sutro loses 3rd of workforce in ADC biotech's 2nd round of layoffs this year | ||
| 29.09. | HHS division refers Harvard for potential debarment as funding clash takes new form | ||
| 29.09. | BioLineRx forges partnership with Norwegian biotech to advance cancer candidate | ||
| 29.09. | After surprise trial listing, Applied Tx still doesn't have any updates on its rare disease asset | ||
| 29.09. | Gilead pumps up virology pipeline with drug transporter deal | ||
| 29.09. | IO lays off 50% of employees after FDA derails cancer vaccine approval plan | ||
| 29.09. | Enanta sees RSV drug fail phase 2b but finds positives in secondaries and subgroup | ||
| 29.09. | MoonLake's stock crashes after high placebo rate eclipses IL-17 drug's phase 3 readouts | ||
| 29.09. | Genmab pays $8B to buy Merus and its phase 3 bispecific that wowed analysts | ||
| 26.09. | Biogen officially ends all AAV gene therapy work, prompting team restructure | ||
| 26.09. | New nine-figure ARPA-H programs seek to deliver custom gene editing treatments to more patients | ||
| 26.09. | Eli Lilly opens incubator site in San Diego, with 'several' biotechs already on board | ||
| 26.09. | Fierce Biotech's Fierce 15 | ||
| 26.09. | US biotechs think twice about EU licensing deals amid Trump's drug pricing campaign | ||
| 25.09. | NIH earmarks $87M for new organoid center as pivot away from animal testing continues | ||
| 25.09. | Eli Lilly withdraws phase 2b trial of $1.9B obesity bet before starting enrollment | ||
| 25.09. | Heidelberg to lay off 75% of staff after milestone becomes millstone | ||
| 24.09. | Average biopharma biobucks decline, while upfront deal payments rise: SRS Acquiom | ||
| 24.09. | Sparrow flies forward with $95M series B for midstage diabetes asset | ||
| 24.09. | Harmony's pivotal Fragile X trial flops as high placebo response creates discord | ||
| 24.09. | uniQure hopes to launch 1st Huntington's gene therapy next year following phase 1/2 success |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .